SPECS: Safe Pediatric Euglycemia in Cardiac Surgery

NACompletedINTERVENTIONAL
Enrollment

989

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

June 30, 2012

Study Completion Date

January 31, 2014

Conditions
Heart Defects, CongenitalHyperglycemia
Interventions
DRUG

Insulin

Study drug is continuously infused intravenous insulin. Suggested dose is calculated by a computerized infusion algorithm using the participant's blood sugar concentration. The insulin infusion rate is titrated to maintain normal blood sugar. Participants are eligible to receive insulin while they have an in-dwelling arterial catheter.

OTHER

Usual Care

Participants receive standard Cardiac ICU care without tight blood glucose control.

Trial Locations (2)

48109

C.S. Mott Children's Hospital, Ann Arbor

02115

Children's Hospital Boston, Boston

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Boston Children's Hospital

OTHER

NCT00443599 - SPECS: Safe Pediatric Euglycemia in Cardiac Surgery | Biotech Hunter | Biotech Hunter